CX-4945 is a potent and selective orally bioavailable small molecule inhibitor of CK2 that inhibits human umbilical vein endothelial cell migration, tube formation, and blocks CK2-dependent hypoxia-induced factor 1 alpha (HIF-1??) transcription in cancer cells.
More Information Supplier PageCX-4945 is a potent and selective orally bioavailable small molecule inhibitor of CK2 that inhibits human umbilical vein endothelial cell migration, tube formation, and blocks CK2-dependent hypoxia-induced factor 1 alpha (HIF-1??) transcription in cancer cells.
More Information Supplier PageCX-4945 is a potent and selective orally bioavailable small molecule inhibitor of CK2 that inhibits human umbilical vein endothelial cell migration, tube formation, and blocks CK2-dependent hypoxia-induced factor 1 alpha (HIF-1??) transcription in cancer cells.
More Information Supplier PageBMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.
More Information Supplier PageBMS-536924 is an effective inhibitor of IGF-IR, causing a reversion of an IGF-IR – mediated transformed phenotype.
More Information Supplier PageBMS-536924 is an effective inhibitor of IGF-IR, causing a reversion of an IGF-IR – mediated transformed phenotype.
More Information Supplier PageBMS-536924 is an effective inhibitor of IGF-IR, causing a reversion of an IGF-IR – mediated transformed phenotype.
More Information Supplier PageBMS-536924 is an effective inhibitor of IGF-IR, causing a reversion of an IGF-IR – mediated transformed phenotype.
More Information Supplier PageBMS-536924 is an effective inhibitor of IGF-IR, causing a reversion of an IGF-IR – mediated transformed phenotype.
More Information Supplier PageOSI-906 is a potential first-in-class selective small molecule, dual kinase inhibitor of both insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR).
More Information Supplier Page
